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The pharmacokinetic properties of oral and intravenous artesunate (2 mg/kg of body weight) were studied
in 19 adult patients with acute uncomplicated Plasmodium falciparum malaria by using a randomized crossover
design. A sensitive bioassay was used to measure the antimalarial activity in plasma which results from
artesunate and its principal metabolite, dihydroartemisinin. The oral study was repeated with 15 patients
during convalescence. The mean absolute oral bioavailability of the antimalarial agent in patients with acute
malaria was 61% (95% confidence interval [CI], 52 to 70%). The absorption and elimination of oral artesunate
were rapid, with a mean elimination half-life of antimalarial activity of 43 min (95% CI, 33 to 53 min).
Following oral administration to patients with acute falciparum malaria, peak antimalarial activity in plasma
and the area under the plasma concentration-time curve were approximately double those during convales-
cence and the apparent volume of distribution and clearance were approximately half those during convales-
cence (P < 0.005). Acute malaria is associated with a significant reduction in the clearance of artesunate-
associated antimalarial activity.
Artemisinin (qinghaosu) and its derivatives are a major ad-
vance in antimalarial treatment (8). These drugs are increas-
ingly used in southeast Asia for the treatment of multidrug-
resistant Plasmodium falciparum malaria (2, 8, 15, 22).
Artesunate, the most widely available of the artemisinin-re-
lated compounds, is a hemisuccinate derivative of dihydroar-
temisinin (DHA). It may be given parenterally, intravenously,
intramuscularly, orally, or rectally. Oral artesunate is used ei-
ther alone or in combination, usually with mefloquine (15).
Despite considerable use in areas where malaria is endemic,
there are relatively few data on the pharmacokinetics of arte-
sunate in the treatment of malaria (2–4, 6, 9, 13, 21, 27). There
are concerns that the various artesunate formulations may
have different bioavailabilities and that the development of
resistance will be accelerated if suboptimal doses are used (13,
24). Optimization of dosing recommendations is also impor-
tant because of evidence that high doses of parenteral arte-
misinin derivatives (artemether, arteether) are neurotoxic in
experimental mammals (16).
Oral artesunate and artemether, but not artemisinin, are
hydrolyzed rapidly back to the common metabolite DHA,
which is intrinsically more active as an antimalarial agent. Oral
artesunate may be considered mainly a prodrug for DHA, as
the metabolite is the main contributor to overall antimalarial
activity (2, 6). Thus, in order to compare different formulations
of these drugs accurately and to guide the accurate choice of
compound, the bioavailability of the antimalarial agent must
be assessed.
Chemical methods for the assay of DHA and the related
derivatives have a limit of accurate quantitation above the
range of concentrations which provide significant antimalarial
effect. High-performance liquid chromatography (HPLC) with
electrochemical detection (ECD) (14) is considered the “gold
standard,” but this method is difficult, time-consuming, and
expensive. HPLC methods with UV detection and pre- or
postcolumn derivatization are simpler but have limits of de-
tection some 10 times higher than the 50% inhibitory concen-
trations (IC50s) for antimalarial activity. Bioassay gives an al-
ternative and considerably more sensitive measure and
provides important clinical pharmacodynamic information.
However, it does not distinguish between parent drugs and
their active metabolites (20). We have used the sensitive bio-
assay, supplemented by HPLC-ECD, to assess the bioavailabil-
ity and disposition of oral artesunate during acute uncompli-
cated falciparum malaria and during convalescence.
MATERIALS AND METHODS
Patients. This study was conducted in Paholpolpayuhasena Hospital, Kan-
chanaburi, western Thailand, in 1993. Nonpregnant adults (age, .14 years)
hospitalized with uncomplicated acute P. falciparum malaria (26) were included
in the study, provided that they gave fully informed consent and had not received
previous treatment with an artemisinin derivative. Pretreatment with quinine was
checked by a urine dipstick screening method (19). The study was approved by
the ethical and scientific review subcommittee of the Royal Thai Government
Ministry of Public Health.
Clinical procedures. On admission the patients were weighed; a full clinical
examination was conducted; and venous hematocrit, urea and electrolytes, cre-
atinine, liver enzymes, glucose, and lactate levels were measured. Samples for
thick and thin blood smears were taken, and quantitative parasite counts were
recorded.
Drug and sampling regimens. Patients were initially randomized to receive
either oral or intravenous artesunate at a dose of 2 mg/kg of body weight. The
parenteral drug was dispensed as artesunic acid powder at 60 mg per ampoule
(Guilin No. 2 Factory, Guangxi, People’s Republic of China) and was dissolved
in 1 ml of 5% sodium bicarbonate (to form sodium artesunate) and was then
diluted to 5 ml in 5% dextrose and given by intravenous bolus injection. The
50-mg artesunate tablets (Guilin No. 1 Factory; Guangxi, People’s Republic of
China) were crushed, dissolved in water to provide the weight-adjusted dose
(within 62.5 mg), and immediately given to the patient. Blood samples were
* Corresponding author. Mailing address: Faculty of Tropical Med-
icine, Mahidol University, 420/6 Rajvithi Rd., Bangkok 10400, Thai-
land. Phone: (66) 2 246 0832. Fax: (66) 2 246 7795. E-mail: fnnjw
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taken through an indwelling catheter in a forearm vein at 0, 5, 15, 30, 45, 60, 90,
and 120 min and then at 3, 4, 6, 8, 12, 18, and 24 h following drug administration.
A second dose of artesunate (2 mg/kg) was then given by the opposite route, i.e.,
if oral administration was given first, then intravenous administration was given
second. Blood samples were again taken at the same time intervals at which they
were taken on the first day. On day 3, mefloquine (25 mg/kg; Lariam; Roche) was
given to complete the treatment. Vital signs were recorded every 4 h, and
hematocrit and parasitemia levels were measured every 6 h until parasite clear-
ance (defined as the first negative thick film, i.e., no parasites seen, after the
counting of 200 white blood cells). Following recovery and discharge from hos-
pital, the patients were asked to return for a convalescent-phase study. The
hematocrit and blood film for malaria parasites were checked, and, provided the
patient was fully recovered and blood smear negative for malaria parasites, the
same oral artesunate dose (2 mg/kg) was readministered, followed by the same
regimen of blood sampling described above.
Drug assays. Immediately after they were taken, the blood samples were
centrifuged and the plasma was stored at 250°C for up to 1 month and then at
280°C for #48 months until assay. Antimalarial activity in plasma was measured,
as described previously, by an in vitro bioassay for P. falciparum in which anti-
malarial activity is expressed as DHA equivalents (20). The lower limit of quan-
titation of the bioassay was 2.5 ng/ml, and interassay coefficients of variation were
9 to 13% for DHA concentrations in the range from 5 to 50 ng/ml. Dilutions were
used for samples with concentrations of .100 ng/ml. Plasma samples from three
patients (six data series) were also analyzed at the National Centre for Drug
Research, Universiti Sains Malaysia, by HPLC with ECD in the reductive mode
for separate quantification of artesunate and DHA (14). The lower limit of
detection of HPLC-ECD was 4 ng/ml for both artesunate and DHA, and inter-
assay coefficients of variation were 3.1% for artesunate and 5.9% for DHA at
concentrations of 30 and 60 ng/ml, respectively.
Pharmacokinetic and statistical analysis. Open one- and two-compartment
models were fitted to the plasma concentration-time data, and standard phar-
macokinetic parameters were derived. Curve fitting was performed with Win-
Nonlin (User’s guide for WinNonlin; Scientific Consulting, Inc., Cary, N.C.),
which is a weighted, iterative, nonlinear regression procedure. Compartmental
models were chosen on the basis of the Akaike Information Criterion (AIC) and
standard pharmacokinetic equations applied (User’s guide for WinNonlin; Sci-
entific Consulting, Inc.). The area under the curve (AUC) from 0 to 24 h
(AUC0–24) was calculated by using the linear trapezoidal rule. Clearance (CL)
was calculated from the model-independent equation CL/f 5 dose/AUC0–24,
where f is the fraction of the oral dose that is absorbed, and bioavailability was
calculated from the equation (AUC0–24oral 3 dosei.v.)/(AUC0–24i.v. 3 doseoral),
where oral is oral administration and i.v. is intravenous administration.
It was assumed that artesunate was completely converted to DHA (i.e., there
was no other significant route of artesunate elimination) for determination of the
dose in pharmacokinetic analysis of HPLC data for DHA. Visual examination of
frequency plots and, if necessary, the Shapiro-Wilks test were used to determine
the appropriateness of using parametric statistical tests (Student’s t test) or
nonparametric statistical tests (Mann-Whitney and Wilcoxon signed rank tests).
Correlations were assessed by using Pearson’s and Spearman’s correlation coef-
ficients. Analyses were performed by using SPSS 8.0 (SPSS Inc., Chicago, Ill.).
RESULTS
Clinical responses. Twenty adult patients (17 males and 3
females) hospitalized with uncomplicated falciparum malaria
were enrolled in the study. One patient was excluded from the
subsequent analysis because insufficient clinical data were re-
corded. At the time of presentation the patients had been ill
for a median of 3 days (range, 1 to 10 days) with fever, head-
ache, anorexia, nausea, and vomiting. The clinical and labora-
tory findings upon admission are shown in Table 1. The median
parasite clearance time was 32 h (range, 8 to 88 h). All patients
made a rapid and uncomplicated recovery. There were no
significant differences in clinical or laboratory features be-
tween those patients who received oral or intravenous artesu-
nate first (P . 0.04 for all comparisons). Two patients vomited
after administration of the oral dose during the acute phase, at
3 and 0.75 h, respectively, after their individual maximum con-
centrations in serum (Cmaxs) had been reached. Fifteen pa-
tients returned for the convalescent-phase oral dose study a
median of 7 days (range 5 to 31 days) after initial admission.
No patient had malaria parasites on thick films at follow-up.
The characteristics of the 15 patients who returned for fol-
low-up did not differ from those of the 19 patients studied
during the acute phase (P . 0.05). No adverse effects of the
study drug were noted.
Drug measurements. Three patients were found to have
received quinine, one patient was found to have received chlo-
roquine, and one patient was found to have received tetracy-
cline before the study. The bioassay method was able to control
for these potential confounders by calibrating the baseline
plasma sample as having zero DHA equivalents. In these cases
the considerably lower levels of antimalarial activity from qui-
nine, chloroquine, and tetracycline (half-lives, 16 to 18 h, 30 to
60 days, and 8 h, respectively [21, 23]) over the 4 to 8 h during
which artesunate concentrations were measurable was as-
sumed not to have changed. The same approach accommo-
dates the antimalarial action of mefloquine (half-life, 2 to 3
weeks [23]) in the convalescent-phase study samples. The only
other oral drugs taken by the patients immediately before or
during the study were acetaminophen (paracetamol; n 5 8),
ferrous sulfate (n 5 5), folic acid (n 5 3), chlorpheniramine
(n 5 3), vitamins B1, B6, and B12 (n 5 2), metoclopramide (n 5
2), primaquine (n 5 1), mebendazole (n 5 1), and thiabenda-
zole (n 5 1). None of these drugs are known to interact with
artesunate.
Pharmacokinetics. (i) Models. An open two-compartment
model with first-order kinetics gave a good fit for 17 of the data
sets for bioassay with intravenous administration, with a mean
AIC of 147 (95% confidence interval [CI], 137 to 157) (Fig. 1;
Table 2). Fitting of the one-compartment models to these data
sets gave significantly higher mean AIC values (190 [95% CI,
182 to 198]; P , 0.0001). The two remaining data sets, for
bioassay with intravenous administration and HPLC with in-
travenous administration, could be modeled only with a one-
compartment model, with AIC values of #160 and #205, re-
spectively. An open one-compartment model with first-order
absorption and elimination provided a good fit to the plasma
concentration-time data sets for bioassay following oral admin-
istration (Table 3) and the acute-phase oral and convalescent-
phase data sets for the HPLC assay (median AIC, 143; range,
86 to 180). No significant differences were found between the
pharmacokinetic parameters if artesunate was given intrave-
nously first or second (P . 0.05 for all comparisons).
(ii) Absorption. Oral artesunate was absorbed rapidly,
reaching peak antimalarial concentrations in a median of
0.75 h (range 0.5 to 4.0 h) and 1.00 h (range, 0.5 to 4.00 h) for
acute- and convalescent-phase oral doses, respectively (P 5
0.9). Cmaxs ranged between 268 and 2,506 ng of DHA equiv-
alents per ml (mean, 1,021 ng/ml) after acute-phase oral ad-
TABLE 1. Clinical and laboratory findings upon admission
Parameter Median Range
Age (yr) 27 18–41
Wt (kg) 53 41–64
Temp (°C) 38.3 36.5–41.0
Hematocrit (%) 38 21–44
Parasite count (no./ml)a 24,289b 832–185,888
Total serum bilirubin concn (mmol/liter)c 21.1 6.8–48.2
Serum creatinine concn (mmol/liter)d 115 97–141
Plasma lactate concn (mmol/liter)e 2.7 1.3–4.4
Serum albumin concn (g/liter)f 33 24–39
a Counts are (number of asexual parasites/1,000 erythrocytes on thin film 3
percent hematocrit 3 125.6) or (number of asexual parasites/200 white blood
cells on thick film 3 40), assuming that the peripheral white blood cell count is
8.0 3 109/liter.
b Geometric mean.
c Normal range, 3 to 17 mmol/liter.
d Normal range, 70 to 150 mmol/liter.
e Normal range, ,4 mmol/liter.
f Normal range, 35 to 50 g/liter.
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ministration but ranged between 137 and 1,040 ng/ml (mean,
546 ng/ml) after administration during the convalescent phase
(Table 3). Antimalarial activity 5 min after intravenous injec-
tion in patients with acute malaria was considerably higher,
ranging between 2,809 and 9,757 ng/ml (median, 5,100 ng/ml)
(Fig. 1 and 2; Tables 2 and 3). The calculated mean absolute
antimalarial bioavailability of the acute oral dose was 61%
(95% CI, 52 to 70%; range, 30 to 104%).
(iii) Disposition. The mean elimination half-lives of antima-
larial activity were 44 min (95% CI, (38 to 50 min), 43 min
(95% CI, 33 to 53 min) and 50 min (95% CI, 35 to 65 min) for
intravenous, acute-phase oral, and convalescent-phase oral ad-
ministrations, respectively (P . 0.2 for all comparisons).
After intravenous, acute-phase oral, and convalescent-phase
oral administrations for one, two, and three patients, respec-
tively, the antimalarial activity had not reached zero 24 h after
dosing. Assuming ;70% in vivo drug protein binding (11), the
residual low concentrations (median, 4.0 ng of DHA equiva-
lents per ml [range, 1 to 25 ng/ml]) are just below the current
range of in vitro IC50s of DHA for P. falciparum in western
Thailand (A. Brockman, personal communication). Among
the remaining patients the earliest time at which no antima-
larial activity was detected was a median of 8 h (range, 6 to
24 h) for intravenous administration, 8 h (range, 6 to 18 h) for
acute-phase oral administration, and 8 h (range, 3 to 14 h) for
convalescent-phase oral administration.
The estimated CL of antimalarial activity following acute-
phase oral artesunate administration was positively correlated
with that following acute-phase intravenous administration
(r 5 0.65; P 5 0.003) but not with that following convalescent-
phase oral artesunate administration (P 5 0.8). There were no
significant relationships between any of the derived pharma-
cokinetic variables and clinical and laboratory measurements
upon admission (P . 0.05).
Acute-phase oral administration gave peak antimalarial ac-
tivities and AUC0–24 values which were approximately twice as
high as those during the convalescent phase and, thus, corre-
sponding lower estimates for apparent volume of distribution
and CL that were approximately half those during the conva-
lescent phase (Table 3). The convalescent-phase AUC0–24 was
a mean of 61% (95% CI, 40 to 82%) of the acute-phase
AUC0–24 after oral administration. The ratios of convalescent-
phase oral AUC0–24/acute-phase AUC0–24 after oral adminis-
FIG. 1. Mean (standard error [SE]) log antimalarial activity in DHA equivalents following acute-phase intravenous (), acute-phase oral (F), and convalescent-
phase oral (E) artesunate administration in patients with acute falciparum malaria.
TABLE 2. Means and 95% CIs or medians and ranges for
pharmacokinetic variables for acute-phase
intravenous administrationa
Variable Value for acute-phaseintravenous administrationb
Cmax (ng/ml)......................................................... 8,240 (2,188–70,763)
c
k10 (/h)
d ................................................................ 3.15 (1.08–20.69)c
k12 (/h)
d ................................................................ 3.12 (0.61–17.03)c
k21 (/h)
d ................................................................ 2.37 (2.02–2.72)
t1/2 (h) ................................................................... 0.73 (0.62–0.83)
a (h21)d ................................................................ 7.24 (2.64–38.84)c
b (h21)d ................................................................ 1.01 (0.88–1.11)
MRT (h21)........................................................... 0.76 (0.64–0.88)
Vc (liter/kg)
d......................................................... 0.27 (0.20–0.34)
VSS (liter/kg) ........................................................ 0.61 (0.50–0.72)
CL (1/kg/h) .......................................................... 0.83 (0.70–0.96)
AUC0–24 (ng z h/ml)............................................ 3,013 (2,482–3,544)
a Bioassay results are in DHA equivalents (n 5 19 subjects). Abbreviations:
Cmax, predicted concentration at time zero; k10, elimination rate constant; k12,
rate constant, central to peripheral compartment; k21, rate constant, peripheral
to central compartment; t1/2, half-life (0.693/b and 0.693/k10 for two- and one-
compartment models, respectively); a, alpha rate constant; b, beta rate constant;
MRT, mean residence time; Vc, volume of distribution of central compartment
per kilogram of body weight); VSS, volume of distribution at steady state per
kilogram of body weight; CL, clearance per kilogram of body weight; AUC0–24,
area under the curve from 0 to 24 h. Values are means (95% CIs) unless
indicated otherwise.
b To convert DHA equivalents in nanograms per milliliter to nanomoles per
liter, multiply by 3.517.
c Values are medians (ranges).
d Refers only to data from the 17 two-compartmental models; the remaining
variables refer to the 19 one- and two-compartmental models combined.
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tration did not correlate significantly with any clinical or lab-
oratory measurements (P . 0.05). There were no significant
differences between acute-phase and convalescent-phase oral
treatment regimens in times to Cmax absorption rate constants,
and lag times (P $ 0.19).
(iv) HPLC data. The HPLC assays for artesunate and DHA
for three patients yielded 12 data sets (Table 4). Although the
sample size is small, the data suggest that artesunate is rapidly
and largely converted to DHA (Fig. 2). For the three patients
the AUC0–24s for DHA after oral administration during the
acute phase as a percentage of the AUC0–24 determined by the
antimalarial bioassay were 72, 95, and 102%, respectively. For
each of these patients the time to Cmax after drug administra-
tion was longer for DHA than for artesunate.
DISCUSSION
Oral artesunate is a widely used, very well tolerated, and
highly effective antimalarial agent. Its rapid and consistent
activity against multidrug-resistant strains of P. falciparum has
led to its increasing use in areas such as southeast Asia where
there is widespread resistance to other antimalarial drugs (8,
15). Other members of this class, artemisinin, artemether, ar-
teether, and dihydroartemisinin, are also in clinical use. There
are several different pharmaceutical formulations of each drug,
and they may have significantly different pharmacokinetic
properties (13). The present pharmacokinetic data on the orig-
inal Chinese oral artesunate formulation, which is by far the
most widely used formulation and which has been used in most
TABLE 3. Means and 95% CIs or medians and ranges for pharmacokinetic variables for acute- and convalescent-phase oral administrationa
Variable Acute phaseb Convalescent phaseb P value
No. of subjects 19 15
AIC 158 (148–168) 130 (118–142)
Tmax (h) 0.75 (0.50–4.00)
c 1.00 (0.50–4.00)c NS
Cmax (ng/ml) 1,021 (775–1267) 546 (379–715) 0.013
Tlag (h) 0.30 (0.16–0.44) 0.36 (0.18–0.54) NS
t1/2 (h) 0.71 (0.55–0.87) 0.84 (0.49–1.09) NS
k01 (h
21) 1.86 (0.80–20.87)c 3.44 (0.60–29.52)c NS
k10 (/h
21) 1.13d (0.96–1.30) 1.08d (0.78–1.38) NS
V/f (liters/kg) 1.33d (1.02–1.64) 3.15d (2.02–4.28) 0.005
CL/f (liters/kg/h) 1.38d (1.03–1.73) 2.54d (2.10–2.98) 0.003
AUC0–24 (ng z h/ml) 1,738
d (1,412–2,064) 886d (733–1,039) 0.0005
a Bioassay results are in DHA equivalents. Abbreviations are the same as defined in footnote a of Table 2 and as follows: AIC, Akaike Information Criterion; Tmax,
observed time to Cmax; Cmax, maximum observed concentration; Tlag, absorption lag time; k01, absorption rate constant; V/f, total apparent volume of distribution per
kilogram of body weight; f, fraction of the oral drug that is absorbed; NS, not significant. Values are means (95% CIs) unless indicated otherwise.
b To convert DHA equivalents in nanograms to milliliter to nanomoles per liter, multiply by 3.517.
c Values are medians (ranges).
d Significantly (P , 0.01) different from mean for acute-phase intravenous administration (Table 2). For oral and convalescent-phase volume of distribution data
compared with the estimated steady-state volume of distribution data, P was not significant P . 0.02.
FIG. 2. Relationship between total plasma antimalarial activity by bioassay () in DHA equivalents and concentrations of artesunate (E) and DHA (F) in plasma
measured by HPLC-ECD following acute-phase oral artesunate administration for one patient.
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of the clinical trials of artesunate, provide a benchmark against
which other formulations and derivatives may be compared.
Comparison of bioactivity and HPLC results suggests that
oral artesunate is largely converted to the more active antima-
larial metabolite DHA, as has been documented for oral arte-
mether (20). Oral artesunate is absorbed rapidly, with absolute
bioavailability averaging 61%, although there is considerable
interpatient variation. The coefficient of variation of the anti-
malarial activity AUC following oral administration was simi-
lar in patients with acute malaria (42%) and in patients in the
convalescence phase (34%) (Table 3), which indicates that
much of the interindividual variation is due to patient factors
and not variation in disease severity. The absolute bioavailabil-
ity of artesunate cannot be compared with those of other
artemisinin derivatives as there are no intravenous formula-
tions of these other drugs.
The absolute antimalarial bioavailability of artesunate found
in this study is lower than the DHA bioavailability reported
recently for Vietnamese adults with uncomplicated falciparum
malaria (mean, 82%; 95% CI, 71 to 92%) and vivax malaria
(mean, 85%; 95% CI, 68 to 101%) as determined by a less
sensitive but reliable HPLC assay with UV detection (3, 4).
The bioavailability reported here represents total antimalarial
activity, whereas the estimates of Batty et al. (3, 4) represent
only the bioavailability of DHA. Assuming that artesunate is
entirely converted to DHA, the sum of published AUCs for
artesunate and DHA after intravenous and oral administration
(3, 4), corrected for their molecular weights, can be used to
estimate the corresponding total antimalarial bioavailability.
This yields antimalarial bioavailability estimates of 56 and 71%
for falciparum and vivax malaria patients, respectively, consis-
tent with the results presented here. The derived pharmacoki-
netic parameters were also similar in both studies. Four factors
may confound comparisons between pharmacokinetic studies
of artesunate. First, the calculation of the AUC0–24 after in-
travenous administration is highly dependent on the extrapo-
lated concentration at time zero, and therefore, errors in the
concentration at time zero will have a profound effect on the
calculated bioavailability. Indeed, the AUC for the first 15 min
after dosing is nearly half (mean, 42%; 95% CI, 37 to 47%) of
the total AUC in the first 24 h. Second, disease severity may
vary and the patients recruited into this study may have had
more severe disease than those described earlier (4), with
higher levels of parasitemia and higher serum creatinine and
bilirubin concentrations. Third, the study drugs may have dif-
ferent contents. Batty et al. (3, 4) found that 50-mg artesunate
tablets (which were from the same source as those used in this
study) had a mean artesunate concentration of 44.8 mg (95%
CI, 42.8 to 46.7 mg). If this correction is applied to our data,
the estimated mean absolute bioavailability of oral artesunate
was 68% (95% CI, 58 to 78%). Fourth, different assay methods
may give different results.
Vietnamese children who had moderately severe malaria
and who were given 3 mg of oral artesunate per kg had lower
mean Cmax (664 ng of DHA equivalents per ml) and AUC
(1,286 ng z h/ml) values, as determined by the same bioassay,
compared with those achieved in the present study. Children
may have higher levels of drug clearance than adults (6).
The significantly lower AUC0–24 during the convalescent
phase probably did not result from a reduction in absolute oral
bioavailability per se; indeed, the opposite would have been
more likely as visceral blood flow and intestinal absorption are
reduced in patients with acute malaria and should have re-
turned to normal during the convalescent phase (12, 17). The
reduction in AUC probably results from expansion in the ap-
parent volume of distribution and improved systemic clearance
on recovery with increased presystemic (first-pass), intestinal,
and hepatic metabolism. In patients with acute malaria the
apparent volume of distribution of protein-bound basic drugs,
such as quinine and presumably the artemisinin derivatives, is
reduced as a consequence of increased binding to a-1-acid
glycoprotein (11, 18). It is not clear whether hepatic artesunate
and DHA metabolism is autoinduced, as has been described
for artemisinin itself (1, 9). This study cannot distinguish be-
tween the pharmacokinetic effects of disease and autoinduc-
tion.
Artesunate is readily hydrolyzed to DHA, probably by blood
esterases and the hepatic cytochrome P450 3A4, as is the case
with the closely related compounds artelinic acid and arteether
(7, 25). Artemether is also probably biotransformed by intes-
tinal cytochrome P450 3A4 (M. A. van Agtmael, V. Gupta, and
C. J. van Boxtel, Abstr. 38th Intersci. Conf. Antimicrob Agents
Chemother., abstr. A-081, p. 26, 1998). If artesunate is simi-
larly metabolized, interindividual variability in intestinal P450
3A4 activity may be important in determining bioavailability.
Comparison of bioassay and HPLC results suggests that the
majority of antimalarial activity can be explained by DHA,
which is cleared predominantly by hepatic biotransformation
either to biologically inert glucuronides (such as DHA-gluc-
uronide (with the glucuronide at the 12 position) or to metab-
olites which lack the peroxide bridge necessary for antimalarial
activity (5, 7, 10, 11; K. Ilett, T. M. E. Davis, K. T. Batty, J. L.
TABLE 4. Summary of results of HPLC assays for artesunate and DHAa
Variable
Oral administration Convalescent phase Intravenous administration
Artesunateb DHAc Artesunate DHA Artesunate DHA
No. of patients 3 3 1 1 2 2
AUC0–24 (ng z h/ml) 210 (70–667) 1,334 (1,018–2,673) 317 829 1,056 (322–1789) 3,999 (2,360–5,637)
k01 (h
21) 10.50 (2.55–47.91) 9.47 (2.36–9.69) 0.618 11.95
k10 (h
21) 1.29 (1.05–1.97) 1.06 (1.02–1.46) 0.623 0.248 3.00 (0.96–5.05) 1.93 (1.02–2.84)
thalf (h) 0.54 (0.35–0.66) 0.65 (0.47–0.68) 1.11 2.79 0.43 (0.14–0.72) 0.46 (0.24–0.68)
Tlag (h) 0.19 (0.00–0.25) 0.22 (0.14–0.45) 0.27 0.25
Tmax (h) 0.50 (0.25–0.50) 0.75 (0.5–1.0) 3 1
Cmax (ng/ml)
d 198 (61–510) 1,052 (817–2,853) 98 294
V (liters/kg) 7.1 (1.8–31.4) 1.49 (0.68–1.69) 8.75 7.75 3.23 (0.62–5.84) 0.50 (0.36–0.64)
CL (liters/kg/h) 9.51 (2.99–32.80) 1.50 (0.75–2.24) 6.32 2.41 4.38 (3.19–5.58) 0.84 (0.66–1.01)
a Values are medians (ranges). Abbreviations are as defined in footnotes a of Tables 2 and 3.
b To convert artesunate in nanograms per milliliter to nanomoles per liter, multiply by 2.601.
c To convert DHA in nanograms per milliliter to nanomoles per liter, multiply by 3.517.
d Cmax is the observed value for the oral administration data sets and the extrapolated value for the intravenous administration data sets.
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Maggs, B. K. Park, T. Q. Binh, L. T. A. Thu, N. C. Hung, and
G. Edwards, Abstr. 5th Int. ISSX Meet., 1998). DHA clearance
may be reduced in patients with malaria as the disease affects
the function of a broad range of hepatic and possibly intestinal
drug biotransformation pathways (5, 7, 12, 17; Ilett et al.,
Abstr. 5th Int. ISSX Meet., 1998).
Following artesunate administration, antimalarial activity
was eliminated rapidly, with terminal half-lives of approxi-
mately 45 min. Despite this, once-daily administration to pa-
tients with acute malaria has proved highly effective and gives
parasite and fever clearance times equivalent to those achieved
with twice-daily administration (15). Transient exposure to
parasiticidal concentrations of the drug twice per parasite asex-
ual life cycle are sufficient for an optimum pharmacodynamic
effect. However, the considerable interindividual variability in
the profile of the concentration of the drug in blood argues in
favor of using a dose higher than 2 mg/kg, at least initially, for
the treatment of acute uncomplicated falciparum malaria.
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